Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S. Kusne, J.S. Dummer, N. Sing, S. Iwatsuki, L. Makowka, C. Esquivel, et al.
Infections after liver transplantation. An analysis of 101 consecutive cases.
Medicine, 67 (1988), pp. 132-143
[2.]
I. Losada, V. Cuervas-Mon, I. Millán, D. Diego.
Infección precoz en el trasplante hepático: incidencia, gravedad, factores de riesgo y sensibilidad antibiótica de los aislados bacterianos.
Enferm Infecc Microbiol Clin, 20 (2002), pp. 422-430
[3.]
T. Pumarola, A. Moreno, M. Blanes.
Grupo de Estudio de la Infección en el Trasplante (GESITRA) y Organización Nacional de Trasplantes (ONT). Conferencia de consenso: Criterios de selección del donante de órganos respecto a la transmisión de infecciones.
Med Clin (Barc), 112 (1999), pp. 711-715
[4.]
J. Ayats, J.M. Cisneros, J.L. Pérez, J. De la Torre.
Evaluación de las enfermedades infecciosas en el candidato a un trasplante de órgano sólido.
Enferm Infecc Microbiol Clin, 20 (2002), pp. 448-461
[5.]
P.M. Arnow, G.C. Carandang, R. Zabner, M.E. Irwin.
Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation.
Clin Infect Dis, 22 (1996), pp. 997-1003
[6.]
H.A. Valantine, S.Z. Gao, S.G. Menon, D.G. Renlund, S.A. Hunt, P. Oyer, et al.
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study.
Circulation, 100 (1999), pp. 61-66
[7.]
D.F. Martin, J. Sierra-Madero, S. Walmsley, R.A. Wolitz, K. Macey, P. Georgiou, et al.
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
N Engl J Med, 346 (2002), pp. 1119-1126
[8.]
A.P. Limaye, L. Corey, D.M. Koelle, C.L. Davis, M. Boeckh.
Emergence of ganciclovir resistant cytomegalovirus disease among recipients of solid-organ transplants.
Lancet, 356 (2000), pp. 645-649
[9.]
D. Samuel, R. Muller, G. Alexander, L. Fassati, B. Ducot, J.P. Benhamou, et al.
Liver transplantation in European patients with the hepatitis B surface antigen.
N Engl J Med, 329 (1993), pp. 1842-1847
[10.]
R.P. Perrillo, T. Wright, J. Rakela, G. Levy, E. Schiff, R. Gish, et al.
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.
Hepatology, 33 (2001), pp. 424-432
[11.]
D. Seehofer, N. Rayes, T. Steinmuller, A.R. Muller, U. Settmacher, R. Neuhaus, et al.
Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.
Liver Transpl, 7 (2001), pp. 976-982
[12.]
M.P. Manns, P. Neuhaus, G.F. Atkinson, K.E. Griffin, S. Barnass, J. Vollmar, et al.
Famciclovir treatment of hepatitis B infection following liver transplantation: A long-term, multi-centre study.
Transpl Infect Dis, 3 (2001), pp. 16-23
[13.]
L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, M.R. Lucey.
The association between hepatitis C infection and survival after orthotopic liver transplantation.
Gastroenterology, 122 (2002), pp. 889-896
[14.]
A.A. Prachalias, A. Pozniak, C. Taylor, P. Srinivasan, P. Muiesan, J. Wendon, et al.
Liver transplantation in adults coinfected with HIV.
Transplantation, 72 (2001), pp. 1684-1688
[15.]
A. Humar, D. Kumar, A.M. Caliendo, G. Moussa, A. Ashi-Sulaiman, G. Levy, et al.
Clinical impact of human herpesvirus 6 infection after liver transplantation.
Transplantation, 73 (2002), pp. 599-604
[16.]
C. Lumbreras, V. Cuervas-Mons, P. Jara, A. Del Palacio, V.S. Turrion, C. Barrios, et al.
Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation.
J Infect Dis, 174 (1996), pp. 583-588
[17.]
R. Patel, D. Portela, A.D. Badley, W.S. Harmsen, J.J. Larson-Keller, D.M. Ilstrup, et al.
Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation.
Transplantation, 62 (1996), pp. 926-934
[18.]
N. Singh, F.Y. Chang, T. Gayowski, I.R. Marino.
Infections due to dematiaceous fungi in organ transplant recipients: Case report and review.
Clin Infect Dis, 24 (1997), pp. 369-374
[19.]
J. Fortun, P. Martin-Davila, M.E. Alvarez, A. Sanchez-Sousa, C. Quereda, E. Navas, et al.
Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients.
Transplantation, 71 (2001), pp. 145-149
[20.]
R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennet, R.E. Greene, J.W. Oestmann, et al.
Voriconazol versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med, 347 (2002), pp. 408-415
[21.]
Maertens J, Raad I, Sable CA, Ngai A, Berman R, Patterson TF, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 de septiembre de 2000.
[22.]
J. Torre-Cisneros, C. Herrero, E. Canas, J.M. Reguera, M. De La Mata, M.A. Gomez-Bravo.
High mortality related with Staphylococcus aureus bacteremia after liver transplantation.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 385-388
[23.]
G.A. Papanicolaou, B.R. Meyers, J. Meyers, M.H. Mendelson, W. Lou, S. Emre, et al.
Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality.
Clin Infect Dis, 23 (1996), pp. 760-766
[24.]
D.L. Paterson, N. Singh, J.D. Rihs, C. Squier, B.L. Rihs, R.R. Muder.
Control of an outbreak of infection due to extended-spectrum beta-lactamase producing Escherichia coli in a liver transplantation unit.
Clin Infect Dis, 33 (2001), pp. 126-128
[25.]
J.H. Blusch, C. Patience, U. Martin.
Pig endogenous retroviruses and xenotransplantation.
Xenotransplantation, 9 (2002), pp. 242-251
[26.]
M. Bernabeu-Wittel, M. Naranjo, J.M. Cisneros, E. Canas, M.A. Gentil, G. Algarra, et al.
Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 173-180
[27.]
Ministerio de Sanidad y Consumo. Orden SCO/709/2002, de 22 de marzo, por la que se convoca la concesión de ayudas para el desarrollo de Redes Temáticas de Investigación Cooperativas.
Boletín Oficial del Estado, 80 (2002), pp. 12742-12746
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
